Adverse effects and radiological manifestations of new immunotherapy agents

Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature

(2017) S. Cuzzubbo et al.   EUROPEAN JOURNAL OF CANCER

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma.

(2017) R. A. Ibrahim et al.   JOURNAL OF CLINICAL ONCOLOGY

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

(2016) Stéphane Champiat et al.   CLINICAL CANCER RESEARCH

Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma

(2016) Yudai Okano et al.   ENDOCRINE JOURNAL

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

PD-1 inhibitor gastroenterocolitis: case series and appraisal of ‘immunomodulatory gastroenterocolitis’

(2016) Raul S Gonzalez et al.   HISTOPATHOLOGY

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

(2016) L. Marthey et al.   Journal of Crohns & Colitis

Systematic review: colitis associated with anti-CTLA-4 therapy

(2015) A. Gupta et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Pseudoprogression and Immune-Related Response in Solid Tumors

(2015) Victoria L. Chiou et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights

(2015) Alexander Faje   Pituitary

Ipilimumab-Associated Colitis: CT Findings

(2013) Kyung Won Kim et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

(2013) M. Nishino et al.   CLINICAL CANCER RESEARCH

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

(2013) Kyung Won Kim et al.   INVESTIGATIONAL NEW DRUGS

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways

(2008) Brian T. Fife et al.   IMMUNOLOGICAL REVIEWS